Acute hepatitis associated with treatment of peyronie's disease with potassium para-aminobenzoate (Potaba)

Journal of Sexual Medicine

Volumn 5, Issue 12, 2008, Pages 2967-2969

  Roy, Joey ^a,b   Carrier, Serge ^a  

^a MCGILL UNIVERSITY   (Canada)

^b NONE   (Canada)

Author keywords

Drug Reaction; Hepatitis; Peyronie's Disease; Potassium Para Aminobenzoate

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMINOTRANSFERASE; COLCHICINE; DIMENHYDRINATE; FINASTERIDE; OXAZEPAM; TAMSULOSIN;

ACUTE HEPATITIS; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; CANADA; CASE REPORT; CLINICAL FEATURE; CORPUS CAVERNOSUM; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ECHOGRAPHY; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; JAUNDICE; LIVER TOXICITY; MALE; NAUSEA; NEGRO; PENIS; PEYRONIE DISEASE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SURGICAL TECHNIQUE;

EID: 57449099025     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.00918.x     Document Type: Article

References (15)

1. Hasche-Klunder R. Treatment of Peyronie's disease with para-aminobenzoacidic potassium. Urologe A 1978;17:224-7.
2. Carson CC. Potassium para-aminobenzoate for the treatment of Peyronie's disease: Is it effective? Tech Urol 1997;3:135-9.
3. Weidner W, Hauck EW, Schnitker J. Peyronie's disease potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: A prospective, placebo-controlled, randomized study. Eur Urol 2005;47:530-6.
4. Hauck EW, Diemer T, Schmelz HU, Weidner W. A critical analysis of nonsurgical treatment of Peyronie's disease. Eur Urol 2006;49:987-97.
5. Trost LW, Gur S, Hellstrom WJ. Pharmacological management of Peyronie's disease. Drugs 2007;67:527-45.
6. Bella AJ, Perelman MA, Brant WO, Lue TF. Peyronie's disease. J Sex Med 2007;4:1527-38.
7. Kantor GR, Ratz JL. Liver toxicity from potassium para-aminobenzoate. J Am Acad Dermatol 1985;13:671-2.
8. Borum M, Nsien E, Zimmerman H. Hepatotoxicity from paraaminobenzoic acid. Dig Dis Sci 1991;36:1793.
9. Mesnil A, Lewden B, Dumortier J, Cuche M, Euvrard P, Dorez D, Vial T. Atteinte hépatique aiguëassociée àla prise de para-aminobenzoate de potassium (Potaba®) (Liver injury due to potassium para-aminobenzoate (Potaba®)). Gastroenterol Clin Biol 2004;28:1295-6.
10. Zarafonetis CJ, Dabich L, DeVol EB, Rossi C, Skovronski JJ. Potassium para-aminobenzoate and liver function test findings. J Am Acad Dermatol 1986;15:144-9.
11. Fremond L, Diebold MD, Thiefin G. Hépatite aiguëpseudo-angiocholitique probablement induite par la tamsulosine (Acute pseudoangiocholitic hepatitis probably induced by tamsulosin). Gastroenterol Clin Biol 2006;30:1224.
12. Martinez de Guzman M, Martinez-Crespo JJ. Hepatitis por finasterida (Finasteride-induced hepatitis). Farm Hosp 2006;30:385.
13. Shindel AW, Bullock TL, Brandes S. Urologist practice patterns in the management of Peyronie's disease: A nationwide survey. J Sex Med 2007 [Epub ahead of print].
14. Fitch WP 3rd, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease-a placebo-controlled pilot study. J Sex Med 2007;4:477-84.
15. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Safety 2007;30:277-94.